Publication: A fungus-derived purpactin A as an inhibitor of TMEM16A chloride channels and mucin secretion in airway epithelial cells
dc.contributor.author | Chantapol Yimnual | en_US |
dc.contributor.author | Saravut Satitsri | en_US |
dc.contributor.author | Baiq Nila Sari Ningsih | en_US |
dc.contributor.author | Vatcharin Rukachaisirikul | en_US |
dc.contributor.author | Chatchai Muanprasat | en_US |
dc.contributor.other | Faculty of Medicine Ramathibodi Hospital, Mahidol University | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Prince of Songkla University | en_US |
dc.date.accessioned | 2022-08-04T11:21:32Z | |
dc.date.available | 2022-08-04T11:21:32Z | |
dc.date.issued | 2021-07-01 | en_US |
dc.description.abstract | TMEM16A is a Ca2+-activated Cl- channel involved in mucus secretion in inflamed airways and proposed as a drug target for diseases associated with mucus hypersecretion including asthma. This study aimed to identify novel inhibitors of TMEM16A-mediated Cl- secretion in airway epithelial cells from a collection of compounds isolated from fungi indigenous in Thailand and examine its potential utility in mitigating airway mucus secretion using Calu-3 cells as a study model. Screening of > 400 fungal metabolites revealed purpactin A isolated from a soil-derived fungus Penicillium aculeatum PSU-RSPG105 as an inhibitor of TMEM16A-mediated Cl- transport with an IC50 value of ~2 µM. A consistent inhibitory effect of purpactin A on TMEM16A were observed regardless of TMEM16A activators or in the presence of an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII), a negative regulator of TMEM16A. In addition, purpactin A did not affect cell viability, epithelial barrier integrity and activities of membrane transport proteins essential for maintaining airway hydration including CFTR Cl- channels and apical BK K+ channels. Intriguingly, purpactin A prevented a Ca2+-induced mucin release in cytokine-treated airway cells. Taken together, purpactin A represents the first class of TMEM16A inhibitor derived from fungus, which may be beneficial for the treatment of diseases associated with mucus hypersecretion. | en_US |
dc.identifier.citation | Biomedicine and Pharmacotherapy. Vol.139, (2021) | en_US |
dc.identifier.doi | 10.1016/j.biopha.2021.111583 | en_US |
dc.identifier.issn | 19506007 | en_US |
dc.identifier.issn | 07533322 | en_US |
dc.identifier.other | 2-s2.0-85104575566 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/78954 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85104575566&origin=inward | en_US |
dc.subject | Pharmacology, Toxicology and Pharmaceutics | en_US |
dc.title | A fungus-derived purpactin A as an inhibitor of TMEM16A chloride channels and mucin secretion in airway epithelial cells | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85104575566&origin=inward | en_US |